214 related articles for article (PubMed ID: 29230688)
1. Therapeutic effects of histone deacetylase inhibitors on kidney disease.
Chun P
Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688
[TBL] [Abstract][Full Text] [Related]
2. The roles of histone deacetylases in kidney development and disease.
Liu H
Clin Exp Nephrol; 2021 Mar; 25(3):215-223. PubMed ID: 33398599
[TBL] [Abstract][Full Text] [Related]
3. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
Bush EW; McKinsey TA
Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
6. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
Van Beneden K; Geers C; Pauwels M; Mannaerts I; Wissing KM; Van den Branden C; van Grunsven LA
Toxicol Appl Pharmacol; 2013 Sep; 271(2):276-84. PubMed ID: 23707763
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L
Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors in kidney development and disease.
Brilli LL; Swanhart LM; de Caestecker MP; Hukriede NA
Pediatr Nephrol; 2013 Oct; 28(10):1909-21. PubMed ID: 23052657
[TBL] [Abstract][Full Text] [Related]
10. The mechanism and potential targets of class II HDACs in angiogenesis.
Hou F; Li D; Yu H; Kong Q
J Cell Biochem; 2018 Apr; 119(4):2999-3006. PubMed ID: 29091298
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
12. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
13. The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3
Wu WP; Tsai YG; Lin TY; Wu MJ; Lin CY
BMC Nephrol; 2017 Jul; 18(1):225. PubMed ID: 28693431
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
Weïwer M; Lewis MC; Wagner FF; Holson EB
Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
[TBL] [Abstract][Full Text] [Related]
15. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Khan S; Jena G; Tikoo K
Exp Mol Pathol; 2015 Apr; 98(2):230-9. PubMed ID: 25576297
[TBL] [Abstract][Full Text] [Related]
16. Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
Galán M; Varona S; Orriols M; Rodríguez JA; Aguiló S; Dilmé J; Camacho M; Martínez-González J; Rodriguez C
Dis Model Mech; 2016 May; 9(5):541-52. PubMed ID: 26989193
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases.
Zhang L; Cao W
J Mol Med (Berl); 2022 Jan; 100(1):43-51. PubMed ID: 34698870
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone deacetylases for heart diseases.
Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
[TBL] [Abstract][Full Text] [Related]
19. Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.
Sleiman SF; Basso M; Mahishi L; Kozikowski AP; Donohoe ME; Langley B; Ratan RR
Expert Opin Investig Drugs; 2009 May; 18(5):573-84. PubMed ID: 19388875
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
Dekker FJ; van den Bosch T; Martin NI
Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
